Journal of Applied Physiology, Vol 72, Issue 5 1845-1853, Copyright © 1992 by American Physiological Society

ARTICLES

Characterization of thromboxane and prostacyclin effects on pulmonary vascular resistance

J. W. Barnard, R. A. Ward, W. K. Adkins and A. E. Taylor
Department of Physiology, College of Medicine, University of South Alabama, Mobile 36688.

Although thromboxane and prostacyclin (PGI2) have long been described as major controllers of pulmonary vascular resistance, little has been reported on the characteristics of the interactions between the two arachidonic acid products. The current study uses segmental vascular resistance and compliance measurements to evaluate the actions of thromboxane and PGI2 in isolated blood-perfused rat lung. The thromboxane analogue U-46619 increases pulmonary vascular resistance by increasing only small artery resistance and decreases pulmonary vascular compliance in the middle compartment. Among the vascular effects of U-46619 are a maximum increase in resistance (RmaxU-46619) of 60.3 +/- 15.6 cmH2O.l-1.min.100 g-1 and a concentration required for 50% of maximum increase (K0.5,U-46619) of 1.60 +/- 0.85 nM for small artery resistance, a minimum vascular compliance (CminU-46619) of -0.93 +/- 0.58 cmH2O, and a K0.5,U-46619 of 1.10 +/- 1.60 nM for middle compartment compliance. Similar results were obtained for total resistance and total compliance. The effects of PGI2 on thromboxane-induced resistance and compliance changes were evaluated using K0.5,PGI2, RmaxPGI2, and CmaxPGI2 at each dose of thromboxane. PGI2 was more effective in reversing the thromboxane constriction at higher concentrations of thromboxane. These data show that the absolute concentration of PGI2 and thromboxane and not a simple ratio of thromboxane to PGI2 determines vascular tone.

This article has been cited by other articles:

				L. G. Chicoine, E. Tzeng, R. Bryan, S. Saenz, M. L. Paffett, J. Jones, C. R. Lyons, T. C. Resta, L. D. Nelin, and B. R. Walker Intratracheal adenoviral-mediated delivery of iNOS decreases pulmonary vasoconstrictor responses in rats J Appl Physiol, November 1, 2004; 97(5): 1814 - 1822. [Abstract] [Full Text] [PDF]

				R. L. Conhaim, K. E. Watson, D. M. Heisey, G. E. Leverson, and B. A. Harms Thromboxane receptor analog, U-46619, redistributes pulmonary microvascular perfusion in isolated rat lungs J Appl Physiol, January 1, 2004; 96(1): 245 - 252. [Abstract] [Full Text] [PDF]

				R. P. Jankov, R. Belcastro, E. Ovcina, J. Lee, H. Massaeli, S. J. Lye, and A. K. Tanswell Thromboxane A2 Receptors Mediate Pulmonary Hypertension in 60% Oxygen-exposed Newborn Rats by a Cyclooxygenase-independent Mechanism Am. J. Respir. Crit. Care Med., July 15, 2002; 166(2): 208 - 214. [Abstract] [Full Text] [PDF]

				J. K. Wright, L. T. Kim, T. E. Rogers, and R. H. Turnage Prostaglandins potentiate U-46619-induced pulmonary microvascular dysfunction J Appl Physiol, April 1, 2000; 88(4): 1167 - 1174. [Abstract] [Full Text] [PDF]

				S. D. Thies, R. S. Corbin, C. D. Goff, O. A. R. Binns, S. A. Buchanan, K. S. Shockey, H. F. Frierson Jr, J. S. Young, C. G. Tribble, and I. L. Kron Thromboxane Receptor Blockade Improves Oxygenation in an Experimental Model of Acute Lung Injury Ann. Thorac. Surg., May 1, 1996; 61(5): 1453 - 1457. [Abstract] [Full Text]